Pricing Log in Create free account

BridgeBio Oncology Therapeutics, Inc (BBOT) vs Immuneering Corporation (IMRX)

BridgeBio Oncology Therapeutics, Inc and Immuneering Corporation are both Biotechnology companies. BridgeBio Oncology Therapeutics, Inc and Immuneering Corporation are of similar size ($236.5M and $235.5M). Across the 9 metrics below, Immuneering Corporation leads on 6 and BridgeBio Oncology Therapeutics, Inc on 3.

Valuation

Metric BBOT IMRX Biotechnology median
P/E n/m n/m 8.50
P/S n/m 732.69 9.71
P/B 0.70 1.22 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 259.82 9.21
Earnings yield (97.87%) (28.97%) (33.15%)
Free cash flow yield (67.14%) (24.54%) (25.50%)

Profitability

Metric BBOT IMRX Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (252.10%) (52.15%) (56.36%)
Return on assets (96.69%) (47.31%) (48.04%)
Return on invested capital (127.66%) (97.14%) 0.00%

Growth

Metric BBOT IMRX Biotechnology median
Revenue growth (TTM) — (84.76%) 6.02%
EPS growth (last fiscal year) 99.93% 37.75% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BBOT IMRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.69 19.47 4.72
Net debt to EBITDA 2.93 2.94 0.96

Dividend

Metric BBOT IMRX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BBOT IMRX Biotechnology median
Market cap 236.52m 235.50m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack